Clinical Trials Logo

Fertility Preservation clinical trials

View clinical trials related to Fertility Preservation.

Filter by:
  • Recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06157619 Recruiting - Clinical trials for Fertility Preservation

Vitrification of Oocytes Matured by CAPA-IVM

Start date: December 2023
Phase:
Study type: Observational [Patient Registry]

It has been reported that the potential of In Vitro matured oocytes might be affected by the vitrification process. In fact, the freezing and thawing procedures routinely used in IVF laboratories, have not yet been adapted to oocytes coming from early antral follicles (normally used for In Vitro Maturation). This study aims to compare 2 existing protocols for the Vitrification of In Vitro matured oocytes.

NCT ID: NCT06074796 Recruiting - Transgenderism Clinical Trials

The Determinants of Fertility Preservation in TRANSgender Patients.

FP-TRANS
Start date: September 25, 2023
Phase:
Study type: Observational

The study is monocentric, retrospective, non-interventional and does not involve human subjects. The main objective is to compare the profiles of transgender patients who undergo fertility preservation with those who do not. The secondary objectives are to define the rate of recourse to fertility preservation, determine the proportion of patients wishing to become parents. Statistical analysis will be carried out with a view to highlighting significant determinants in transgender patients by comparing those who undergo fertility preservation with those who do not. The data will have been collected during routine consultations as part of the transition process for transgender patients. This is taking place in the reproductive medicine department of the regional university hospital centre in Nancy.

NCT ID: NCT05945407 Recruiting - Clinical trials for Endometrial Neoplasms

Fertility-sparing Therapy for Patients With Stage IA Endometrial Cancer

Start date: August 1, 2016
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to explore the feasibility and outcome of fertility-sparing therapy in Stage IA G1-G2 Endometrial Cancer with less than 1/2 myometrial invasion. Researchers will render participants indication-extended fertility-sparing therapy. Researchers will compare the myometrial invasion group with the no myometrial invasion group to see if it is possible to propose an extension indication of fertility-sparing therapy for endometrial cancer.

NCT ID: NCT05885048 Recruiting - Cancer Clinical Trials

Impact of Gonadotoxic Therapies on Fertility

FertiTOX
Start date: December 1, 2023
Phase:
Study type: Observational [Patient Registry]

The goal of this observational study is to learn how gonadotoxic treatments (chemotherapies, radiotherapies or immunotherapies) affect the fertility status of participants with cancer. The main questions it aims to answer are: - in females, if cancer therapies reduce the Anti-Müllerian hormone (AMH) concentration (ovarian reserve); - in males, if cancer therapies reduce sperm concentration (sperm quality).

NCT ID: NCT05443737 Recruiting - Cancer Clinical Trials

Evaluation of a Telehealth Oncofertility Care Intervention in Adolescent and Young Adult Cancer Patients

Start date: January 1, 2022
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the effectiveness of a multi-component intervention to improve young cancer survivors' engagement in goal-concordant oncofertility care, concurrently with observing and gathering information on how the intervention is implemented. The investigators hypothesize that implementation of the intervention will result in increased young cancer survivors' engagement in goal-concordant oncofertility care.

NCT ID: NCT05372549 Recruiting - Clinical trials for Fertility Preservation

Correlation of Oxidative Stress and Oocyte Quality in Fertility Preservation

Ooxyd
Start date: June 1, 2022
Phase: N/A
Study type: Interventional

Whether it is for oncology or personal reasons, fertility preservation allows participants to preserve their oocytes (eggs) at their current age and condition for a better chance of having a baby in the future. In order to proceed with fertility preservation, participants will need to undergo in vitro fertilization (IVF), which is standard practice, and take stimulation medication to stimulate production of more follicles. The combination of both Rekovelle and Menopur for fertility preservation may increase ovarian response to stimulation and increase the number of oocytes retrieved to give better chances of embryos once the oocytes will be fertilized. The goal in this study is to understand the effect of oxydative stress on the quality of oocytes. For the purpose of the study and to evaluate this connection, serum levels of oxidative stress and cf-DNA in your blood will be measured. Oocyte quality will also be assessed with Magenta, a prediction tool utilizing artificial intelligence (AI). This method is non-invasive and has no risks on the oocytes.

NCT ID: NCT04904263 Recruiting - Cancer Clinical Trials

Advisory Board on Cancer, Infertility and Pregnancy

ABCIP
Start date: May 22, 2021
Phase:
Study type: Observational

The Advisory Board on Cancer, Infertility and Pregnancy provides a platform where physicians from all over the world can request recommendations regarding the medical care of pregnant women diagnosed with cancer or regarding fertility preservation. The platform will contain different national advisory boards, with their own coordinator and members, as well as an overarching international advisory board with an international coordinator and members from different national boards. To investigate the impact of this platform, a year after its launch, data regarding the incoming requests will be extracted from the website, as well as all recommendation letters.

NCT ID: NCT03954197 Recruiting - Breast Cancer Clinical Trials

Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients

PRIMIV
Start date: September 9, 2014
Phase: N/A
Study type: Interventional

Oocyte vitrification after in vitro maturation (IVM) is one of the main techniques for preserving female fertility before chemotherapy for breast cancer. In this technique, originally developed for patients with ovarian pathology, polycystic ovarian syndrome, induction of an LH peak has been shown to improve outcomes. Young women with breast cancer, who are candidates for urgent fertility preservation, do not have ovarian pathology. The objective of the present study is to assess whether the absence of therapeutic intervention prior to oocyte retrieval for IVM in these patients is at least as effective as the injection of hCG or GnRH agonist used in routine practice.

NCT ID: NCT02895165 Recruiting - Pregnancy Clinical Trials

PREgnancy and FERtility Registry

PREFER
Start date: November 2012
Phase:
Study type: Observational [Patient Registry]

The PREgnancy and FERtility (PREFER) study is a comprehensive program aiming to optimize care and improve knowledge around the topics of fertility preservation and pregnancy issues in young breast cancer patients. The program was initiated at the National Institute for Cancer Research, IRCCS AOU San Martino - IST in Genova (Liguria Region, Italy) and then it has been spread to other Italian Institutions under the umbrella of the Gruppo Italiano Mammella (GIM) study group. It is composed of two distinctive studies, one assessing fertility (i.e. PREFER-FERTILITY) and the other pregnancy (PREFER-PREGNANCY) issues. Hence, two different study protocols were developed under the umbrella of the PREFER registry. PREFER-FERTILITY aims to obtain and centralize data about the preferences and choices of young cancer patients on the fertility preservation strategies available in Italy. Furthermore, it aims to assess the outcomes of patients undergoing one or more strategies for fertility preservation in terms of success of the techniques (i.e. recovery of ovarian function, number of cryopreserved oocytes, post-treatment pregnancies) and safety (i.e. long-term survival outcomes). PREFER-PREGNANCY has two main objectives: 1) to obtain and centralize data on the management of breast cancer diagnosed during pregnancy, the obstetrical and paediatric care of children born after prior in utero exposure to anticancer treatments, and the long-term survival outcomes of these patients; 2) to obtain and centralize data on the clinical outcomes of breast cancer survivors that achieve a pregnancy after prior diagnosis and treatment of breast cancer.

NCT ID: NCT02595255 Recruiting - Lymphoma Clinical Trials

AMH as a Predictor of Infertility Risk in Children With Cancer (CHANCE)

CHANCE
Start date: April 2014
Phase:
Study type: Observational

While most of the children spontaneously recover menstruation or experienced normal puberty after chemotherapy, their ovarian reserve may be impaired by treatment inducing future infertility. Fertility preservation is currently proposed for selected prepubertal patients with a high risk of premature ovarian failure after treatment (mostly conditioning regimen for bone marrow transplantation). For patients with low or moderate risks, counselling is very difficult and no fertility preservation procedure is usually proposed for these patients as no marker of the ovarian reserve has been validated in this young population to assess the individual risk. The primary objective of the study is to prevent long-term treatment-related infertility by detecting the young patients who normally progressed to menarche but have a reduced ovarian reserve. These patients may benefit from particular follow-up and fertility preservation procedure.